Park DW, Kwon O, Jang JS, et al. - Among Korean patients (n = 800) hospitalized for acute coronary syndromes with or without ST elevation and reserved for invasive management, researchers assessed clinically significant bleeding at 12 months among those randomly allocated to receive, in a 1:1 ratio, ticagrelor (180 mg loading dose, 90 mg twice daily thereafter) or clopidogrel (600 mg loading dose, 75 mg daily thereafter) in this multicenter trial. Both the treatment groups did not significantly differ in terms of the incidence of death from cardiovascular causes, myocardial infarction, or stroke. A higher incidence of clinically significant bleeding was reported in relation to standard-dose ticagrelor vs clopidogrel treatment in Korean acute coronary syndrome patients intended to receive early invasive management. Exercising caution was recommended while interpreting a numerically higher incidence of ischemic events.